BioAmber Company Profile (NYSE:BIOA)

About BioAmber (NYSE:BIOA)

BioAmber logoBioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.

Industry, Sector and Symbol:
  • Sector: Basic Materials
  • Industry: Specialty Chemicals
  • Sub-Industry: N/A
  • Symbol: NYSE:BIOA
  • CUSIP: N/A
  • Web:
  • Market Cap: $30.1 million
  • Outstanding Shares: 37,102,000
Average Prices:
  • 50 Day Moving Avg: $0.48
  • 200 Day Moving Avg: $1.63
  • 52 Week Range: $0.32 - $6.50
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $10.54 million
  • Price / Sales: 2.01
  • Book Value: $1.86 per share
  • Price / Book: 0.31
  • EBITDA: ($24,980,000.00)
  • Net Margins: -221.82%
  • Return on Equity: -56.55%
  • Return on Assets: -21.56%
  • Debt-to-Equity Ratio: 0.45%
  • Current Ratio: 1.50%
  • Quick Ratio: 1.03%
  • Average Volume: 1.85 million shs.
  • Beta: 2.72

Frequently Asked Questions for BioAmber (NYSE:BIOA)

What is BioAmber's stock symbol?

BioAmber trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIOA."

How were BioAmber's earnings last quarter?

BioAmber Inc. (NYSE:BIOA) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.03. The business earned $4.12 million during the quarter, compared to analysts' expectations of $4.09 million. BioAmber had a negative return on equity of 56.55% and a negative net margin of 221.82%. View BioAmber's Earnings History.

When will BioAmber make its next earnings announcement?

BioAmber is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for BioAmber.

Where is BioAmber's stock going? Where will BioAmber's stock price be in 2017?

1 analysts have issued twelve-month price objectives for BioAmber's stock. Their forecasts range from $3.00 to $3.00. On average, they expect BioAmber's share price to reach $3.00 in the next year. View Analyst Ratings for BioAmber.

Are investors shorting BioAmber?

BioAmber saw a increase in short interest during the month of September. As of September 29th, there was short interest totalling 2,326,092 shares, an increase of 42.9% from the September 15th total of 1,628,222 shares. Based on an average daily trading volume, of 2,101,819 shares, the short-interest ratio is presently 1.1 days. Currently, 5.5% of the company's stock are sold short.

Who are some of BioAmber's key competitors?

Who are BioAmber's key executives?

BioAmber's management team includes the folowing people:

  • Raymond J. Land, Chairman of the Board
  • Fabrice Orecchioni, President, Chief Operating Officer
  • Richard P. Eno, Chief Financial Officer, Director
  • Mario Settino, Chief Financial Officer
  • Michael A. Hartmann, Executive Vice President
  • James Millis, Chief Technology Officer
  • Robert Frost, Director
  • Kurt W. Briner, Independent Director
  • Heinz Haller, Independent Director
  • Ellen B. Richstone, Independent Director

How do I buy BioAmber stock?

Shares of BioAmber can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioAmber's stock price today?

One share of BioAmber stock can currently be purchased for approximately $0.57.

MarketBeat Community Rating for BioAmber (NYSE BIOA)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  107 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  177
MarketBeat's community ratings are surveys of what our community members think about BioAmber and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioAmber (NYSE:BIOA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $3.00 (424.48% upside)
Consensus Price Target History for BioAmber (NYSE:BIOA)
Price Target History for BioAmber (NYSE:BIOA)
Analysts' Ratings History for BioAmber (NYSE:BIOA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017Cowen and CompanySet Price TargetHold$3.00HighView Rating Details
3/13/2017AltaCorp CapitalDowngradeOutperform -> SpeculativeMediumView Rating Details
8/7/2016Canaccord GenuityReiterated RatingBuy$5.50N/AView Rating Details
3/28/2016Credit Suisse GroupBoost Price TargetOutperform$15.00 -> $17.00N/AView Rating Details
1/5/2016HC WainwrightReiterated RatingBuy$18.00N/AView Rating Details
1/5/2016Rodman & RenshawInitiated CoverageBuy$18.00N/AView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for BioAmber (NYSE:BIOA)
Earnings by Quarter for BioAmber (NYSE:BIOA)
Earnings History by Quarter for BioAmber (NYSE BIOA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.16)N/AView Earnings Details
8/3/20176/30/2017($0.17)($0.20)$4.09 million$4.12 millionViewListenView Earnings Details
5/9/20173/31/2017($0.13)($0.31)$3.65 million$2.12 millionViewListenView Earnings Details
3/16/201712/31/2016($0.19)($0.31)$3.77 million$0.63 millionViewN/AView Earnings Details
11/3/2016Q216($0.22)($0.26)$3.75 million$3.66 millionViewN/AView Earnings Details
8/9/2016Q116($0.27)($0.25)$2.37 million$2.50 millionViewN/AView Earnings Details
3/14/2016Q415($0.35)($0.40)$0.98 million$1.11 millionViewN/AView Earnings Details
11/4/2015Q315($0.41)($0.27)$2.30 million$0.35 millionViewN/AView Earnings Details
3/12/2015Q414($0.39)($0.48)($0.31) millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.40)($0.41)$0.47 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.40)$0.40$0.45 million$0.42 millionViewN/AView Earnings Details
3/13/2014($0.36)($0.45)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioAmber (NYSE:BIOA)

No earnings estimates for this company have been tracked by


Dividend History for BioAmber (NYSE:BIOA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for BioAmber (NYSE:BIOA)
Insider Ownership Percentage: 8.33%
Institutional Ownership Percentage: 37.40%
Insider Trades by Quarter for BioAmber (NYSE:BIOA)
Institutional Ownership by Quarter for BioAmber (NYSE:BIOA)
Insider Trades by Quarter for BioAmber (NYSE:BIOA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/18/2017Michael A HartmannInsiderBuy10,000$0.48$4,800.00View SEC Filing  
8/9/2017Mario SettinoCFOBuy15,000$0.53$7,950.00View SEC Filing  
11/9/2016George Frederick John GosbeeDirectorBuy25,000$3.87$96,750.00View SEC Filing  
11/8/2016Kurt W BrinerDirectorBuy10,000$3.84$38,400.00View SEC Filing  
5/24/2016Kurt W BrinerDirectorBuy1,000$3.69$3,690.00View SEC Filing  
5/23/2016Kurt W BrinerDirectorBuy21,015$3.61$75,864.15View SEC Filing  
5/11/2016Jean-Francois HucCEOBuy10,000$3.22$32,200.00View SEC Filing  
5/9/2016Kenneth W WallDirectorBuy13,227$3.11$41,135.97View SEC Filing  
5/6/2016Michael A HartmannEVPBuy3,000$3.44$10,320.00View SEC Filing  
12/3/2015Jean-Francois HucCEOSell27,278$8.11$221,224.58View SEC Filing  
12/3/2015Michael A. HartmannEVPSell21,477$8.11$174,178.47View SEC Filing  
8/14/2015Michael A HartmannEVPBuy1,500$6.75$10,125.00View SEC Filing  
8/11/2015Jean-Francois HucCEOBuy4,000$6.18$24,720.00View SEC Filing  
8/10/2015Raymond J LandDirectorBuy1,500$6.71$10,065.00View SEC Filing  
5/6/2015Jean-Francois HucCEOBuy8,800$9.00$79,200.00View SEC Filing  
5/6/2015Kurt W BrinerDirectorBuy10,000$9.00$90,000.00View SEC Filing  
5/6/2015Michael A HartmannEVPBuy1,100$9.00$9,900.00View SEC Filing  
12/11/2014Kenneth W WallDirectorBuy3,000$9.20$27,600.00View SEC Filing  
12/10/2014Kenneth W WallDirectorBuy5,000$9.30$46,500.00View SEC Filing  
11/10/2014Kurt W BrinerDirectorBuy15,000$9.35$140,250.00View SEC Filing  
9/9/2014Kurt W BrinerDirectorBuy5,000$12.00$60,000.00View SEC Filing  
8/25/2014Kurt W BrinerDirectorBuy14,250$11.50$163,875.00View SEC Filing  
8/11/2014Kurt W BrinerDirectorBuy2,980$11.45$34,121.00View SEC Filing  
7/16/2014Jean-Francois HucCEOBuy4,000$12.00$48,000.00View SEC Filing  
7/16/2014Michael A HartmannEVPBuy3,000$12.00$36,000.00View SEC Filing  
5/12/2014Andrew P AshworthCFOBuy3,000$10.00$30,000.00View SEC Filing  
5/12/2014Michael A HartmannEVPBuy2,500$10.05$25,125.00View SEC Filing  
11/14/2013Kurt W BrinerDirectorBuy7,200$6.95$50,040.00View SEC Filing  
9/3/2013Michael A HartmannEVPBuy2,000$4.63$9,260.00View SEC Filing  
8/29/2013Jean-Francois HucCEOBuy5,000$4.25$21,250.00View SEC Filing  
8/15/2013Kurt W BrinerDirectorBuy13,000$5.49$71,370.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for BioAmber (NYSE:BIOA)
Latest Headlines for BioAmber (NYSE:BIOA)
DateHeadline logoBioAmber Inc. (BIOA) Short Interest Up 42.9% in September - October 17 at 1:04 AM logoHow Does Investing In BioAmber Inc (BIOA) Impact Your Portfolio? - October 10 at 5:51 PM logoHow Does Investing In BioAmber Inc (BIOA) Impact Your Portfolio? - October 10 at 5:51 PM logoReviewing Innospec (IOSP) & BioAmber (BIOA) - September 19 at 12:48 AM logoForm 8-K BioAmber Inc. For: Sep 11 - - September 16 at 4:15 PM logoBioAmber Announces New Chief Executive Officer - September 14 at 5:14 PM logoAnalyzing BioAmber (BIOA) and Its Rivals - September 13 at 6:22 PM logoBioAmber Inc. Receives Notice of Non-Compliance from the NYSE - September 13 at 5:42 PM logoBRIEF-Sabby Management LLC reports 6.15 pct passive stake in BioAmber inc - SEC filing‍ - September 13 at 3:07 AM logoForm SC 13G BioAmber Inc. Filed by: SABBY MANAGEMENT, LLC - - September 12 at 4:50 PM logoBRIEF-NN Group N.V. reports 15.91 pct passive stake in Bioamber - September 8 at 10:00 PM logoKronos Worldwide (KRO) versus BioAmber (BIOA) Head-To-Head Review - September 2 at 2:26 AM logoBioAmber, Inc. :BIOA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 - August 25 at 6:18 PM logoHead to Head Review: Ferro Corporation (FOE) versus BioAmber (BIOA) - August 14 at 12:52 PM logoBioAmber (BIOA) Prices $11M Offering of Common Stock, Warrants - August 8 at 9:23 PM logoBRIEF-Bioamber prices public offering of 14.7 mln shares at $0.75/shr - August 8 at 9:23 PM logoMid-Afternoon Market Update: Michael Kors Gains On Earnings Beat; Commercial Vehicle Shares Slide - Nasdaq - August 8 at 4:20 PM logoMid-Day Market Update: Stocks Turn Higher; Depomed Shares Plummet - Nasdaq - August 8 at 4:20 PM logoBioAmber Inc. Announces US$11 Million Underwritten Offering of Common Stock and Warrants - MarketWatch - August 8 at 4:20 PM logoBioAmber Inc. Announces US$11 Million Underwritten Offering of Common Stock and Warrants - August 8 at 4:20 PM logoBioAmber Inc. Announces Underwritten Offering of Common Stock and Warrants - MarketWatch - August 8 at 3:05 AM logoBioAmber (BIOA) Announces Underwritten Common Offering - August 7 at 10:05 PM logoBRIEF-BioAmber announces underwritten offering of common stock and warrants - August 7 at 5:04 PM logoBioAmber Inc. Announces Underwritten Offering of Common Stock and Warrants - August 7 at 5:04 PM logoBioAmber's (BIOA) Management on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 6 at 4:02 PM logoBioAmber announces record revenues for the second quarter 2017 and purchase of Mitsui equity stake in Sarnia Joint ... - PR Newswire (press release) - August 4 at 9:50 PM logoBioAmber Inc. (BIOA) Issues Earnings Results - August 4 at 8:58 PM logoEdited Transcript of BIOA earnings conference call or presentation 3-Aug-17 12:30pm GMT - August 3 at 11:02 PM logoInvestor Network: BioAmber, Inc. to Host Earnings Call - August 3 at 6:01 PM logoBioAmber announces record revenues for the second quarter 2017 and purchase of Mitsui equity stake in Sarnia Joint Venture - August 3 at 6:01 PM logoBioAmber reports 2Q loss - August 3 at 6:01 PM logoBioAmber Announces Webcast of Fiscal Second Quarter 2017 Financial Results - August 1 at 5:25 PM logoBioAmber Inc. (BIOA) Set to Announce Earnings on Monday - July 31 at 8:11 AM logoGlobal Organic Acid Market By Type (Acetic Acid, Citric Acid, Formic Acid and Lactic Acid), By End Uses (Industrial ... - PR Newswire (press release) - July 27 at 10:03 PM logoGlobal Bio-Based Chemicals Market Forecast 2017-2025 - PR Newswire (press release) - July 20 at 11:11 PM logoSuccinic Acid - Global Strategic Business Report 2017 - Rising Demand for Bio-Plastics: Opportunity for Bio-Succinic Acid Market - July 16 at 9:11 PM logoComparing BioAmber (NYSE:BIOA) and Kraton Corporation (KRA) - July 9 at 8:22 AM logoBioAmber (NYSE:BIOA) & Rayonier Advanced Materials (RYAM) Head-To-Head Comparison - July 7 at 8:06 AM logoBioAmber (BIOA) Announces Launch of BIO-SA Pharmaceutical Grade - - June 16 at 4:39 PM logoBioAmber (BIOA) Announces Launch of BIO-SA Pharmaceutical Grade - June 15 at 5:43 PM logoTMX Group Equity Financing Statistics - May 2017 - June 7 at 4:12 PM logoGlobal Organic Acid Market, Competition Forecast and Opportunities, 2026 - Research and Markets - May 29 at 9:13 AM logoBioAmber Announces Changes to its Board of Directors, the Appointment of a Chief Financial Officer and the Results ... - PR Newswire (press release) - May 17 at 8:59 PM logoLaw Offices of Howard G. Smith Reminds BioAmber Inc. Investors of Pending Lawsuit and Upcoming Lead Plaintiff ... - Business Wire (press release) - May 17 at 8:59 PM logoBioAmber (BIOA) Names New CFO and Announces Changes to Board of Directors - May 15 at 4:04 PM logoBRIEF-BioAmber says Mario Settino appointed CFO - May 15 at 9:31 AM logoBioAmber (BIOA) Q1 2017 Results - Earnings Call Transcript - Seeking Alpha - May 14 at 4:03 PM logoBioAmber Reports First Quarter 2017 Financial Results - PR Newswire (press release) - May 10 at 8:48 AM logoBioAmber Announces Trading on Toronto Stock Exchange Market Commencing on May 3, 2017 - Special Warrant ... - MarketWatch - May 3 at 6:13 PM logoIMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against BioAmber - PR Newswire (press release) - April 27 at 3:29 PM



BioAmber (BIOA) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.